ArticleAmerican journal of translational research2020
Immunotherapy in anaplastic thyroid cancer.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.Hormones (Athens, Greece) · 2026Article
- New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer.Frontiers in immunology · 2026Review
- Immune evolution and therapeutic vulnerabilities in thyroid cancer: from inflammation to immune escape.Frontiers in immunology · 2026Review
- Review
- Triumph Over Butchery: Guest Editorial for Indian Journal of Surgical Oncology.Indian journal of surgical oncology · 2025Article
- Article
- Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.Discover oncology · 2024Review
- Harnessing Immunity to Treat Advanced Thyroid Cancer.Vaccines · 2023Review
- Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.Cancer immunology, immunotherapy : CII · 2023Review
- Article
- Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance.Frontiers in pharmacology · 2023Article
- Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Frontiers in oncology · 2023Review
- Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy.Neurospine · 2022Article
- Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.Journal of molecular cell biology · 2022Article
- Constructing a thyroid cancer prognostic risk model based on CD8Central-European journal of immunology · 2022Article
- Pyrvinium pamoate can overcome artemisinin's resistance in anaplastic thyroid cancer.BMC complementary medicine and therapies · 2021Article
- New Horizons: Emerging Therapies and Targets in Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2021Review
- Bibliometric Insights in Advances of Anaplastic Thyroid Cancer: Research Landscapes, Turning Points, and Global Trends.Frontiers in oncology · 2021Article
- Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy.Frontiers in molecular biosciences · 2021Article
- The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options.Contemporary oncology (Poznan, Poland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid cancer (ATC) is one of the worst human malignancies, with an associated median survival of only 5 months. It is resistant to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression. Cancer immunotherapy has emerged over the past few decades as a transformative approach to treating a wide variety of cancers. However, immunotherapy for ATC is still in the experimental stage. This review will cover several strategies of immunotherapy and discuss the possible application of these strategies in the treatment of ATC (such as targeted therapy for tumor-associated macrophages, cancer vaccines, adoptive immunotherapy, monoclonal antibodies and immune checkpoint blockade) with the hope of improving the prognosis of ATC in the future.
Indexed as
Identifiers
32269728PMC7137046W3026726498What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.